Short diagnosis-to-treatment (DTI) and circulating tumor DNA (ctDNA) levels in patients with DLBCL are indicative of tumor burden at baseline, according to a study, and this information may be useful for mitigating patient selection bias in clinical trials. “Short DTI largely reflects baseline tumor burden, which can be objectively measured using pretreatment ctDNA levels. Pretreatment ctDNA levels therefore have utility for quantifying and guarding against selection biases in prospective DLBCL clinical trials,” the study authors concluded.

Read more.